Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

On the bright side, Leerink Partners upgraded Regeneron to a “strong-buy,” proving at least one analyst still believes in scientific miracles and stock rebounds. Despite the lukewarm analyst sentiment ...

Leerink Partnrs also issued estimates for NeuroPace’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4) Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges ...